Priya Menon Priya Menon Scientific Media Editor at Curetalk

Myeloma Cure Panel Talk Show: Experts To Talk On IMiD, Proteasome inhibitors, Data on KSP, Daratumumab, BTK inhibitor, BAFF-1,…

We have quite a line-up of topics for our January Cure Panel Talk Show scheduled for 30 January 2013 @ 6pm EST. Eminent myeloma experts, Dr. Shaji K. Kumar from Mayo Clinic, Rochester and Dr. Edward A. Faber would be covering the following on the panel:

 

Dr. Kumar:

  • IMiD/proteasome inhibitors
  • Combination of these drugs and maintenance
  • New drug aspects

Dr. Faber:

  • Robert Orlowski’s data with KSP inhibitor
  • Daratumumab (cd38 antibody) results
  • BTK inhibitors
  • BAFF-1 inhibitor
  • Quick points on
    • Escalating R after relapse from MPR-R
    • Thalidomide/lenalidomide combination data
    • Potential usefulness of cereblon

 

A brief background information on the topics would help in following the panel discussion in January:

KSP Inhibitor

ARRY-520 is a novel selective kinesin spindle protein (KSP) inhibitor which has shown promising clinical activity both as a single agent as well as combined with low-dose dexamethasone in phase II clinical trials in patients with refractory/relapsed myeloma.

ARRY-520 specifically inhibits KSP (kinesin-5 or Eg5), resulting in activation of the spindle assembly checkpoint, induction of cell cycle arrest during the mitotic phase, and apoptosis in actively dividing tumor cells. Because KSP is not involved in postmitotic processes (ie, neuronal transport), ARRY-520 does not cause the peripheral neuropathy often associated with tubulin-targeting agents.

ARRY-520 is a novel agent with a distinct mechanism of action relative to other myeloma drugs and shows promising clinical activity both alone and combined with dexamethasone in relapsed and refractory MM. Based on this evidence of activity, further development of ARRY-520 plus low-dose dexamethasone is warranted in patients who have exhausted other therapeutic options.

Reference: http://www.cancernetwork.com/conference-reports/ash2012/content/article/10165/2119650

Daratumumab (CD 38 antibody)

Daratumumab binds to the CD38 molecule, which is found on the surface of multiple myeloma and other blood cancer cells. Once daratumumab is bound to the CD38 molecule on cancer cells, it signals for the immune system to kill the cells.

Daratumumab shows promise for relapsed and refractory multiple myeloma patients. Results of Phase 1/2 study indicates daratumumab to be effective and safe in heavily pretreated patients. The study results were presented at ASH 2012 by Dr. Dr. Torben Plesner from the Vejle Hospital in Denmark. Dr. Plesner’s slides on the daratumumab trials and results can be viewed here.

Reference: http://www.myelomabeacon.com/tag/daratumumab/

 

Will continue in tomorrow’s post.

Related posts:

  1. Dr. Shaji K Kumar MD, Of Mayo Clinic On The Cure Panel Talk Show on Multiple Myeloma This January
  2. Listen To Myeloma Cure Panel Talk Show HERE!
  3. A Shout Out To Myeloma Cure Panel Talk Show Panelists, Expert, and Participants
  4. Listen HERE! Myeloma Cure Panel Talk Show Broadcast with Dr. Parameswaran Hari as Myeloma Expert
  5. ‘It’s Not About The Cancer Alone, But About A Whole Person’ – Dr. Berenson Speaks on Myeloma Treatment Without Transplant on The Cure Panel Talk Show